Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Wegovy is now positioned as the first and only GLP-1 treatment.

Novo Nordisk (NYSE:NVO) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Novo ...

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of ...

The Ozempic price cut could appease US President Donald Trump, who has pushed for drug companies to lower their prices.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...

(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying ...